Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05673811 · ClinicalTrials.gov registry record · Phase 2
Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
A Phase 2 study of Pancreatic Adenocarcinoma and Metastatic, sponsored by Theriva Biologics SL.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
- 17
- Study locations
NCT05673811: Completed Phase 2 study of Pancreatic Adenocarcinoma and Metastatic, sponsored by Theriva Biologics SL.
NCT05673811 is a Phase 2 study of Pancreatic Adenocarcinoma and Metastatic that has completed, run by Theriva Biologics SL. The registered enrollment target is 112 participants, below the 99,463-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05673811, a Phase 2 study of Pancreatic Adenocarcinoma and Metastatic, has completed, sponsored by Theriva Biologics SL.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
- 17
- Study locations
Study Summary
A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer
Primary Outcome
Time from randomization until death in both arms
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- GENETIC VCN-01
Study Locations (17)
Other
- Hospital Universitari Vall d'Hebron - Barcelona
- Hospital Gregorio Marañon - Madrid
- Hospital Universitario Ramon y Cajal - Madrid
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Universitario Virgen de la Victoria - Málaga
- Hospital General Univesitario de Valencia - Valencia
- Hospital Miguel Servet - Zaragoza
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
- University of California - Davis Cancer Center - Sacramento
Kentucky
- University of Louisville - Brown Cancer Center - Louisville
New York
- Weill Cornell Medical Center - New York
Ohio
- Martha Morehouse Tower - Columbus
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Virginia
- Virginia Cancer Specialists - Fairfax
Andalusia
- Hospital Universitario Virgen del Rocío - Seville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2023-01-10 |
| Est. Completion | 2025-03-28 |
| Phase | Phase 2 |
What the finished NCT05673811 record still lists
NCT05673811 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 99,463-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Gemcitabine is the first listed.
NCT05673811 lists 17 locations in 10 states (Other, California, Kentucky).
Frequently Asked Questions
What is clinical trial NCT05673811 about?
NCT05673811 is a clinical study titled "Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer". A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer
What is the current status of trial NCT05673811?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2023-01-10. Estimated completion is 2025-03-28.
What conditions does trial NCT05673811 study?
This clinical trial studies the following conditions: Pancreatic Adenocarcinoma, Metastatic.
What interventions are being tested in trial NCT05673811?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), VCN-01 (GENETIC).
Who is sponsoring clinical trial NCT05673811?
This trial is sponsored by Theriva Biologics SL, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05673811 being conducted?
This trial has 17 study locations across California, Kentucky, New York, Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05673811's enrollment target sits among peer trials
112 21st of 62 higher than 42 of 62 other Pancreatic Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
RECRUITING · Phase 2
-
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
RECRUITING · Phase 2
-
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
9-ING-41 in Patients with Advanced Cancers
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI